B. McGovern

R. Chung, M. J. Bowen, Christopher E Birch, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients.

A. Wurcel, I. Bica, Meg Bradley, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients.

B. McGovern, D. Pratt, M. Epstein, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.

M. Stein, L. Taylor, Patricia A. Cioe, 2011, Drug and alcohol dependence.

Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.

I. Bica, R. Gandhi, C. Birch, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high‐risk Hispanic population

R. Sterling, B. McGovern, J. Forrester, 2009, HIV medicine.

Antiretroviral drugs and liver injury.

V. Soriano, M. Puoti, Y. Benhamou, 2008, AIDS.

Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?

I. Bica, B. McGovern, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative

A. Mirzazadeh, G. Lauer, M. Hellard, 2016, Open forum infectious diseases.

HCV infection: findings from the InC3 Collaborative

A. Mirzazadeh, M. Hellard, J. Bruneau, 2016 .

Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort

M. Hellard, G. Dore, H. Wedemeyer, 2015, Journal of viral hepatitis.

Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Todd M. Allen, M. Hellard, G. Dore, 2015, The Journal of infectious diseases.

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study

R. Geskus, B. Grady, J. Amin, 2015, Journal of viral hepatitis.

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

R. Geskus, M. Hellard, B. Grady, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate!

B. McGovern, 2011, Gastroenterology.

Evaluation and treatment of the HIV/HCV coinfected patient: a case history and discussion.

B. McGovern, 2002, AIDS patient care and STDs.

Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System

G. Lauer, G. Haney, D. Church, 2015, Annals of Internal Medicine.

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

J. Auniņš, D. Ege, M. Lombardo, 2022, Open forum infectious diseases.

Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals.

P. Sax, A. Wurcel, Hang Lee, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Underascertainment of Acute HCV Infections Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System A Case Series and Chart Review

G. Lauer, G. Haney, D. Church, 2015 .

The association of HIV viral load with indirect markers of liver injury

N. Terrin, B. McGovern, M. Rhee, 2012, Journal of viral hepatitis.

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

D. Snydman, I. Bica, R. Dhar, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study

M. Hellard, B. Grady, G. Dore, 2015, PloS one.

The Epidemiology, Natural History and Prevention of Hepatitis B: Implications of HIV Coinfection

B. McGovern, Barbara H McGovern, 2006, Antiviral therapy.

Chapter 38 – HIV Co-Infection Drug Toxicity

R. Sterling, M. Sulkowski, B. McGovern, 2012 .

Antiretroviral therapy for patients with HIV-hepatitis B virus coinfection.

B. McGovern, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies.

P. Sax, A. Wurcel, Hang Lee, 2005, The Journal of infectious diseases.

Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen.

P. Sax, A. Wurcel, C. Ukomadu, 2003, Journal of acquired immune deficiency syndromes.

What drives hepatitis B virus-related hepatic flares? Virus, T cells--or a bit of both?

B. McGovern, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk of HAART therapy in hepatitis C

I. Bica, B. McGovern, 2002, Hepatology.

Hepatitis C in the HIV-Infected Patient

B. McGovern, 2007, Journal of acquired immune deficiency syndromes.

557 Absolute CD4 T-cell subsets are decreased in HIV-seronegative patients with cirrhosis

B. McGovern, D. Pratt, M. Epstein, 2003 .

Hepatic safety and HAART.

B. McGovern, 2004, Journal of the International Association of Physicians in AIDS Care.

Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection

R. Chung, B. A. Abu Dayyeh, B. McGovern, 2008, Hepatology.

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

M. King, K. Kowdley, D. Cohen, 2015, Journal of hepatology.

Antiretroviral drug resistance mutations in antiretroviral-naive prisoners.

R. D’Aquila, L. Sutton, A. Wurcel, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis

C. Huttenhower, J. Wortman, M. Henn, 2020, Gastroenterology.

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.

J. Wortman, M. Henn, T. Louie, 2022, The New England journal of medicine.

The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridiumdifficile Infection: Current Understanding and Gap Analysis

M. Wilcox, G. Hecht, B. McGovern, 2020, Open forum infectious diseases.

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

J. Wortman, M. Henn, R. Pomerantz, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.

M. Henn, C. Kelly, M. Vulić, 2016, The Journal of infectious diseases.

Epidemiology, clinical manifestations, and diagnosis of pandemic H1N1 influenza ('swine influenza')

M. Hirsch, B. McGovern, A. Thorner, 2009 .

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes

J. Wortman, M. Henn, J. Auniņš, 2018, Open Forum Infectious Diseases.

COHORT PROFILE Cohort Profile : The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts ( InC 3 ) Study

G. Lauer, M. Hellard, G. Dore, 2014 .

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection

C. Kelly, E. Hohmann, David A. Lombardi, 2023, JAMA network open.

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109

K. Garey, E. Hohmann, P. Reese, 2023, JAMA network open.

Syphilis negatively influences the response to hepatitis C virus treatment in an HIV-infected patient.

R. Baden, A. Kim, B. McGovern, 2012, Topics in antiviral medicine.

Cases From the Field Syphilis Negatively Influences the Response to Hepatitis C Virus Treatment in an HIV-Infected Patient 134

J. Stein, D. Wyles, K. Sherman, 2012 .

Case Report From the Field Syphilis Negatively Influences the Response to Hepatitis C Virus Treatment in an HIV-Infected Patient

R. Baden, A. Kim, B. McGovern, 2012 .

From the Field Syphilis Negatively Influences the Response to Hepatitis C Virus Treatment in an HIV-Infected Patient

R. Baden, A. Kim, B. McGovern, 2012 .

Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.

R. Chung, M. J. Bowen, Christopher E Birch, 2009, The Journal of infectious diseases.

High rates of sustained virologic response in acute hepatitis C virus infection are associated with low levels of HCV RNA and rapid virologic clearance

R. Chung, Christopher E Birch, A. Kim, 2009 .

ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials

C. Cooper, T. Berg, M. King, 2014 .

Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-Reply.

Stuart H. Cohen, B. McGovern, T. Louie, 2023, Journal of the American Medical Association (JAMA).

Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.

Stuart H. Cohen, B. McGovern, A. Memişoğlu, 2022, JAMA.

A "one-two punch" leading to hepatitis C seroconversion.

M. J. Bowen, Christopher E Birch, A. Kim, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Acute respiratory distress syndrome complicating Plasmodium vivax malaria.

P. Hassoun, M. Tanios, L. Kogelman, 2001, Critical care medicine.

Acute hepatitis C infection in correctional settings.

G. Lauer, A. Kim, B. McGovern, 2009, Gastroenterology.

Risk of HAART therapy in hepatitis C

I. Leclercq, I. Bica, G. Farrell, 2002, Hepatology.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic

David A. Lombardi, D. Pardi, Stuart H. Cohen, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.